These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37482565)

  • 1. Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic.
    Das AK; Chang E; Paydar C; Broder MS; Orroth KK; Cordey M
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):1985. PubMed ID: 37482565
    [No Abstract]   [Full Text] [Related]  

  • 2. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic.
    Das AK; Chang E; Paydar C; Broder MS; Orroth KK; Cordey M
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):1973-1984. PubMed ID: 37392261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
    Persson R; Cordey M; Paris M; Jick S
    Drug Saf; 2022 Nov; 45(11):1403-1411. PubMed ID: 36151359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
    Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
    Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
    Queiro Silva R; Armesto S; González Vela C; Naharro Fernández C; González-Gay MA
    Dermatol Ther; 2020 Nov; 33(6):e13961. PubMed ID: 32618402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
    Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
    Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
    Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.
    Mease PJ; Calabrese LH; Duffin KC; Haberman RH; Firmino R; Scher JU; Schick L; Winthrop K; Merola JF
    J Rheumatol Suppl; 2021 Jun; 97():24-29. PubMed ID: 34074662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
    Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
    J Comp Eff Res; 2021 Aug; 10(12):989-998. PubMed ID: 34187202
    [No Abstract]   [Full Text] [Related]  

  • 15. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
    Bernardini N; Skroza N; Marchesiello A; Mambrin A; Proietti I; Tolino E; Maddalena P; Marraffa F; Rossi G; Volpe S; Potenza C
    Dermatol Ther; 2022 Oct; 35(10):e15306. PubMed ID: 35100460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
    Ferguson LD; Cathcart S; Rimmer D; Semple G; Brooksbank K; Paterson C; Brown R; Harvie J; Gao X; Radjenovic A; Welsh P; McInnes IB; Sattar N; Siebert S
    Rheumatology (Oxford); 2022 Mar; 61(3):1026-1034. PubMed ID: 34097014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
    [No Abstract]   [Full Text] [Related]  

  • 20. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
    Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.